ClinicalTrials.gg
Enrolling by invitationNCT07859046Updated Oct 5, 2026

18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer

An observational study in Breast Cancer, sponsored by Hunan Cancer Hospital. Enrolling by invitation at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Hunan Cancer Hospital · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Neoplasms by Hunan Cancer Hospital — 10 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Hunan Cancer Hospital.

Planned enrollment
8th of 10
100 · median 200
Started
2024
with 1 other
Observational
10 of 15
7 open now
Registered
15th of 15
by date

Among the 15 studies in Breast Neoplasms by Hunan Cancer Hospital, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, and was the 15th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

10 of the 15 studies in Breast Neoplasms by Hunan Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Neoplasms by Hunan Cancer Hospital, or all of them as a file.
02

Study summary

This study uses FES PET/CT imaging to evaluate estrogen receptor-positive breast cancer. FES PET/CT is a type of imaging that can show whether breast cancer cells have estrogen receptors. The purpose of this study is to see how well FES PET/CT can help doctors: (1) diagnose ER-positive breast cancer, (2) plan the best treatment, and (3) check how well treatment is working. Participants will undergo FES PET/CT scans as part of their regular cancer care or study procedures. The results may help improve how doctors use imaging to guide treatment decisions for patients with ER-positive breast cancer.

Read the detailed description

Estrogen receptor (ER) status is a critical determinant of treatment strategy in breast cancer. While 18F-FDG PET/CT is widely used for metabolic assessment, it cannot directly visualize ER expression. 18F-FES is a radiolabeled estrogen analog that binds specifically to ER, enabling non-invasive visualization and quantification of ER expression in vivo. The combined use of 18F-FDG and 18F-FES PET/CT may provide complementary metabolic and receptor information for diagnosis, treatment planning, and therapeutic response assessment in ER-positive breast cancer.This study aims to evaluate the clinical utility of FES PET/CT in three domains: (1) diagnosis and characterization of ER-positive breast cancer lesions, (2) informing treatment planning by assessing ER expression heterogeneity, and (3) monitoring treatment response through quantitative changes in FES uptake.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • FES, ER-positive, breast cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with suspected or new diagnosed or previously treated ER-positive breast cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) adult female patients aged ≥18 years; (2) ER-positive breast cancer confirmed by pathological ; (3) underwent initial staging with18F-FES PET/CT scans.

Exclusion criteria

Exclusion Criteria:

  • (1)patients with more than two primary tumors; (2) incomplete clinical or pathological records; and (3) inability to complete imaging studies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Diagnostic Performance

    Diagnostic accuracy, The sensitivity, specificity and accuracy of 18F-FES PET/CT were calculated.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartActual
May 9, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859046
Lead sponsor
Hunan Cancer Hospital
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
May 9, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion